Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for female-specific cancers. Its primary asset, palazestrant, is an estrogen receptor antagonist currently being tested in Phase 3 trials for hormone receptor-positive breast cancer both as a standalone therapy and in combination with other cancer drugs. The company is also advancing OP-3136, an oral medication targeting KAT6 protein, which is in early-stage testing for breast and other solid tumors.

entry readiness 48 · WEAK SETUP · exit proximity 0

Value area 8.65–13.00 · 78% of 120d volume overhead · heavy supply